Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Suffers Setback In Its Search For Post-CF Blockbusters

Analysts Doubt Pipeline Potential

Executive Summary

Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.

You may also be interested in...



Vertex Urged To Target Major M&A After Another Rare Disease Failure

After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.

Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.

Vertex Under Pressure To Spend On M&A

The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel